Advertisement

Hodgkin’s Lymphoma

  • J. M. Shammo
  • H. M. Golomb
Chapter

Abstract

Approximately 7000-8000 new cases of Hodgkin’s lymphoma (HL) occur annually in the United States. HL is less common in African-Americans compared to Caucasians (1.6 vs 2.9 cases per 100,000, respectively). HL is a diagnosis made more often in men, with a male to female ratio of 4:3. Its age-specific incidence has been repeatedly reported as bimodal, with the greatest pool in the third decade of life and a second, smaller pool in the fifth and sixth decades. It accounts for 12% of malignant lymphomas and 0.6% of all malignancies in the United States [1].

Keywords

Clin Oncol German Hodgkin Study Group Stanford Versus World Health Organi Lymphocyte Predominance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics. CA Cancer J Clin 52:23–47PubMedCrossRefGoogle Scholar
  2. 2.
    Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernadez AM, Taylor CR, Hamilton AS, Deapen DM, Rappaport EB (1995) Concordance for Hodgkin’s disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 332:413–418PubMedCrossRefGoogle Scholar
  3. 3.
    Tirelli U, Errante D, Dolcetti R, Gloghini A, Serraino D, Vaccer E, Franceschi S, Boiocchi M, Carbone A (1995) Hodgkin’s disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 13:1758–1767PubMedGoogle Scholar
  4. 4.
    World Health Organization (2001) World Health Organization (WHO) classification of tumors book Hodgkin’s lymphoma. WHO, Geneva, pp 238–253Google Scholar
  5. 5.
    Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poopema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H (2000) European task force on lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 95:1889–1899Google Scholar
  6. 6.
    Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos G, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report on a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotwswolds meeting. J Clin Oncol 7:1630–1636PubMedGoogle Scholar
  7. 7.
    Castellino RA, Dunnick NR, Goffinet D, Rosenberg SR, Kaplan HS (1983) Predictive value of lymphography for sites of subdiaphragmatic disease encountered at staging laparotomy in newly diagnosed Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 1:532–536PubMedGoogle Scholar
  8. 8.
    Castellino RA, Hoppe RT, Lank N, Young SW, Newmann C, Rosenberg SA, Kaplan HS (1984) Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin’s disease. Am J Roentgenol 143: 37–41Google Scholar
  9. 9.
    Bogart JA, Chung CT, Mariados NF, Vermont AI, Lemke SM, Grethlein S, Graziano SL (1998) the value of gallium imaging after therapy for Hodgkin’s disease. Cancer 15: 754–759CrossRefGoogle Scholar
  10. 10.
    Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN (1998) 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603–609PubMedGoogle Scholar
  11. 11.
    Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, Bihl H (2001) Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 91:302–310PubMedCrossRefGoogle Scholar
  12. 12.
    Glatstein E, Trueblood HW, Enright LP, Rosenberg SA, Kaplan HS (1970) Surgical staging of abdominal involvement in unselected patients with Hodgkin’s disease. Radiology 97: 425–432PubMedGoogle Scholar
  13. 13.
    Rosenberg S, Kaplan H (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11:5–22PubMedCrossRefGoogle Scholar
  14. 14.
    Fuller L, Hutchison G (1982) Collaborative clinical trial for stage I and II Hodgkin’s disease: significant of mediastinal and nonmediastinal disease in laparotomy and non-laparotomy-staged patients. Cancer Treatment Rep 66:775–787Google Scholar
  15. 15.
    Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS (1998) Second cancers following pediatrie Hodgkin’s disease. J Clin Oncol 16:536–544PubMedGoogle Scholar
  16. 16.
    Valagussa P, Santoro A, Fossati-Bellani F et al (1986) Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol 4:830–837PubMedGoogle Scholar
  17. 17.
    Cimino G, Biti GP, Anselmo AP et al (1989) MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin’s disease. J Clin Oncol 7:732–737PubMedGoogle Scholar
  18. 18.
    Longo DL, Glatstein E, Duffey PL et al (1991) Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease. J Clin Oncol 9:906–917PubMedGoogle Scholar
  19. 19.
    Santoro A, Bonfante V, Bonadonna G (1982) Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease. Ann Intern Med 96:139–143PubMedGoogle Scholar
  20. 20.
    Canellos GP, Anderson JR, Propert KJ et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484PubMedCrossRefGoogle Scholar
  21. 21.
    Santoro A, Bonfante V, Viviani S et al (1996) Subtotal nodal versus involved field irradiation after 4 cycles of ABVD in early stage Hodgkin’s disease (abstract no. 1271). Proc Am Soc Clin Oncol 15:415Google Scholar
  22. 22.
    Klasa R, Connors JM, Fairey R et al (1996) Treatment of early stage Hodgkin’s disease: improved outcome with brief chemotherapy and radiotherapy without staging laparotomy (abstract no. 67). Ann Oncol 7:10CrossRefGoogle Scholar
  23. 23.
    Tesch H, Sieber M, Ruffer JU, Franklin J, Herrman R, Boissevain F, Franke A, Pfreundschuh M, Hossfeld D, Duhmke E, Wolf J, Engert A, Paulus U, Diehl V (1998) 2 cycles of ABVD plus radiotherapy is more effective than radiotherapy alone in early stage Hodgkin’s disease — interim analysis of the HD7 trial of the GHSG (abstract no. 2001). Blood 92:485AGoogle Scholar
  24. 24.
    Liebenhaut MH, Hoppe RT, Efron B, Halpern J, Nelsen T, Rosenberg SA (1989) Prognostic indicator of laparotomy findings in clinical stage I—II supradiaphragmatic Hodgkin’s disease. J Clin Oncol 7:81–91Google Scholar
  25. 25.
    Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F et al (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 7:81–91Google Scholar
  26. 26.
    Canellos GP (1996) Is ABVD the standard regimen for Hodgkin’s disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD? Leukemia 2:S68Google Scholar
  27. 27.
    Bartlett NL, Rosenberg SA, Hoppe RT et al (1995) Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 13:1080–1088PubMedGoogle Scholar
  28. 28.
    Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 10:630–637CrossRefGoogle Scholar
  29. 29.
    Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H (1997) BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s lymphoma study group. Ann Oncol 8:143–148PubMedCrossRefGoogle Scholar
  30. 30.
    Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn R, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M (1998) BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hosgkin’s lymphoma: interim report from a trial of the German Hodgkin’s lymphoma study group. J Clin Oncol 16:3810–3821PubMedGoogle Scholar
  31. 31.
    Fabian CJ, Mansfield CM, Dahlberg S et al (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin’s disease. A Southwest Oncology Group randomized study. Ann Intern Med 120:903–912PubMedGoogle Scholar
  32. 32.
    Loeffler M, Brosteanu O, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik P (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International database on Hodgkin’s disease overview study group. J Clin Oncol 16:818–829PubMedGoogle Scholar
  33. 33.
    Young RC, Canellos GP, Chabner BA, Schein PS, De Vita VT (1973) Maintenance chemotherapy for advanced Hodgkin’s disease in remission. Lancet I:133–139Google Scholar
  34. 34.
    Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10: 210–218PubMedGoogle Scholar
  35. 35.
    Bonfante V, Santoro A, Viviani S, Devizi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G (1997) Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 15:528–534PubMedGoogle Scholar
  36. 36.
    Mauch P, Tarbell N, Skarin A, Rosenthal D, Weinstein H (1987) Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol 5:544–549PubMedGoogle Scholar
  37. 37.
    Roach MD, Kapp DS, Rosenberg SA, Hoppe RT (1987) Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin’s disease. J Clin Oncol 5:550–555PubMedGoogle Scholar
  38. 38.
    Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V (2000) Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 18:2615–2619PubMedGoogle Scholar
  39. 39.
    Lucas JB, Hoppe RT, Horwitz SM, Breslin S, Horning SJ et al (2000) Rituximab is active in lymphocyte predominance Hodgkin’s disease (abstract). Blood 96:3592Google Scholar
  40. 40.
    Rehwald U, Engert A, Diehl V et al (2000) Monoclonal anti-CD20 antibody rituximab (rituxan) for treatment of CD20-positive Hodgkin’s lymphoma: the German experience (abstract). Blood 96:3153Google Scholar
  41. 41.
    Carella A, Santini G, Santoro A et al (1985) Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin’s disease. Eur J Clin Oncol 21:607–613CrossRefGoogle Scholar
  42. 42.
    Jagannath S, Dicke KA, Armitage JO et al (1986) High-dose cyclophosphamide, carmustne, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med 104:163–168PubMedGoogle Scholar
  43. 43.
    Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood 89:814–822PubMedGoogle Scholar
  44. 44.
    Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet 341:1051–1054PubMedCrossRefGoogle Scholar
  45. 45.
    Pfreundschuh MG, Ruffer U, Lathan B et al (1994) DexaBEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimen: a trial of the German Hodgkin’s disease study group. J Clin Oncol 12:580–586PubMedGoogle Scholar
  46. 46.
    Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA, Constine LS, DiPersio JF (1993) One hundred autotransplants for relapsed or refractory Hodgkin’s disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 11:2351–2361PubMedGoogle Scholar
  47. 47.
    Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE, Besinger WI, Martin PJ, Storb R, Sullivan KM, Hansen JA, Thomas ED (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 11:2342–2350PubMedGoogle Scholar
  48. 48.
    Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A, Bishop MR, Armitage JO (1996) High dose chemotherapy following by autologous hematopoietic rescue for Hodgkin’s disease patients following first relapse after chemotherapy. Ann Oncol 7:151–156PubMedCrossRefGoogle Scholar
  49. 49.
    Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Sailes G (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin’s disease in relapse or failure after initial chemotherapy results of the Groupe D’etudes des Lymphomes de L’Adulte H89 trial. J Clin Oncol 20:467–475PubMedCrossRefGoogle Scholar
  50. 50.
    Forman JS (1997) Role of high dose chemotherapy and stem cell transplantation in the management of Hodgkin’s disease. In: Perry MC (ed) American Society of Clinical Oncology Educational Book, WG Saunders Companypp 244–247Google Scholar
  51. 51.
    Horning SJ, Chao NJ, Negrin RS, Hoppe RT, LonG GW, Hu WW, Wong RM, Brown BW, Blume KG (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood 89:801–813PubMedGoogle Scholar
  52. 52.
    Milpied N, Fielding AK, Pearce RM, Ernst P, Gladstone AH (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. J Clin Oncol 14:1291–1296PubMedGoogle Scholar
  53. 53.
    Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Korbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE (2000) Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin’s disease. Bone Marrow Transplant 26:615–620PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • J. M. Shammo
  • H. M. Golomb

There are no affiliations available

Personalised recommendations